Adequate, questionable, and inadequate drug prescribing for older adults at the end of life: a European expert consensus

Lucas Morin, Marie-Laure Laroche, Davide L Vetrano, Johan Fastbom, Kristina Johnell, Lucas Morin, Marie-Laure Laroche, Davide L Vetrano, Johan Fastbom, Kristina Johnell

Abstract

Background: Clinical guidance is needed to initiate, continue, and discontinue drug treatments near the end of life.

Aim: To identify drugs and drug classes most often adequate, questionable, or inadequate for older people at the end of life.

Design: Delphi consensus survey.

Setting/participants: Forty European experts in geriatrics, clinical pharmacology, and palliative medicine from 10 different countries. Panelists were asked to characterize drug classes as "often adequate," "questionable," or "often inadequate" for use in older adults aged 75 years or older with an estimated life expectancy of ≤ 3 months. We distinguished the continuation of a drug class that was previously prescribed from the initiation of a new drug. Consensus was considered achieved for a given drug or drug class if the level of agreement was ≥ 75%.

Results: The expert panel reached consensus on a set of 14 drug classes deemed as "often adequate," 28 drug classes deemed "questionable," and 10 drug classes deemed "often inadequate" for continuation during the last 3 months of life. Regarding the initiation of new drug treatments, the panel reached consensus on a set of 10 drug classes deemed "often adequate," 23 drug classes deemed "questionable," and 23 drug classes deemed "often inadequate". Consensus remained unachieved for some very commonly prescribed drug treatments (e.g., proton-pump inhibitors, furosemide, haloperidol, olanzapine, zopiclone, and selective serotonin reuptake inhibitors).

Conclusion: In the absence of high-quality evidence from randomized clinical trials, these consensus-based criteria provide guidance to rationalize drug prescribing for older adults near the end of life.

Keywords: Drug prescribing; Inappropriate prescribing; Older adults; Palliative care; Quality of care.

Conflict of interest statement

Ethics approval and consent to participate

The regional ethical review Board in Stockholm, Sweden approved the study (decision no. 2015/1341-31/1).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Delphi process to reach consensus about the adequateness of drug prescribing in older people at the end of life
Fig. 2
Fig. 2
Flowchart used to determine consensus among panelists

References

    1. Todd A, Husband A, Andrew I, Pearson SA, Lindsey L, Holmes H. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care. 2017;7(2):113–121. doi: 10.1136/bmjspcare-2015-000941.
    1. Molist Brunet N, Espaulella Panicot J, Sevilla-Sánchez D, Amblàs Novellas J, Codina Jané C, Altimiras Roset J, Gómez-Batiste X. A patient-centered prescription model assessing the appropriateness of chronic drug therapy in older patients at the end of life. Eur Geriatr Med. 2015;6(6):565–569. doi: 10.1016/j.eurger.2015.07.008.
    1. Maddison AR, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. Prog Palliat Care. 2011;19(1):15–21. doi: 10.1179/174329111X576698.
    1. Morin L, Vetrano DL, Rizzuto D, Calderón-Larrañaga A, Fastbom J, Johnell K. Choosing wisely? Measuring the burden of medications in older adults near the end of life: nationwide, longitudinal cohort study. Am J Med. 2017;130(8):927–936.e9. doi: 10.1016/j.amjmed.2017.02.028.
    1. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590–595. doi: 10.1111/j.1532-5415.2007.01124.x.
    1. McNeil MJ, Kamal AH, Kutner JS, et al. The burden of polypharmacy in patients near the end of life. J Pain Symptom Manag. 2016;51(2):178–183.e2. doi: 10.1016/j.jpainsymman.2015.09.003.
    1. Ma G, Downar J. Noncomfort medication use in acute care inpatients comanaged by palliative care specialists near the end of life: a cohort study. Am J Hosp Palliat Care. 2014;31(8):812–819. doi: 10.1177/1049909113506981.
    1. Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, Boyd CM. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655–666. doi: 10.1007/s40266-013-0095-7.
    1. Tjia J, Lapane K. Guideline-based prescribing in frail elderly patients. JAMA Intern Med. 2017;177(2):262–263. doi: 10.1001/jamainternmed.2016.7714.
    1. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–184. doi: 10.1016/S0140-6736(07)61091-5.
    1. (2015) American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 63(11):2227–2246
    1. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–218. doi: 10.1093/ageing/afu145.
    1. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–609. doi: 10.1001/archinte.166.6.605.
    1. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834. doi: 10.1001/jamainternmed.2015.0324.
    1. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648–1654. doi: 10.1001/archinternmed.2010.355.
    1. Kutner JS, Blatchford PJ, Taylor DHJ, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700. doi: 10.1001/jamainternmed.2015.0289.
    1. Gnjidic D, Le Couteur DG, Kouladjian L, et al. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237–253. doi: 10.1016/j.cger.2012.01.006.
    1. Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc. 2008;56:1306–1311. doi: 10.1111/j.1532-5415.2008.01741.x.
    1. Raijmakers NJH, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M. Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer. 2013;21(4):1003–1011. doi: 10.1007/s00520-012-1619-0.
    1. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, Barras M. The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’. Support Care Cancer. 2015;23(1):71–78. doi: 10.1007/s00520-014-2322-0.
    1. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, Zimmermann C, del Giglio A, Riechelmann RP. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313–1318. doi: 10.1007/s00520-010-0947-1.
    1. Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46(4):600–607.
    1. Nyborg G, Jør S, Klovning A, et al. The Norwegian General Practice-Nursing Home criteria (NORGEP-NH) for potentially inappropriate medication use: a web-based Delphi study. Scand J Prim Health Care. 2015;33(2):134–141. doi: 10.3109/02813432.2015.1041833.
    1. Amano K, Maeda I, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Ono S, Yamamoto R, Yamamoto N, Shishido H, Shimizu M, Kawahara M, Aoki S, Demizu A, Goshima M, Goto K, Gyoda Y, Hashimoto K, Otomo S, Sekimoto M, Shibata T, Sugimoto Y, Morita T. The accuracy of physicians’ clinical predictions of survival in patients with advanced cancer. J Pain Symptom Manag. 2015;50(2):139–46.e1. doi: 10.1016/j.jpainsymman.2015.03.004.
    1. White N, Kupeli N, Vickerstaff V, Stone P. How accurate is the ‘Surprise Question’ at identifying patients at the end of life? A systematic review and meta-analysis. BMC Med. 2017;15(1):139. doi: 10.1186/s12916-017-0907-4.
    1. White N, Reid F, Harris A, Harries P, Stone P. A systematic review of predictions of survival in palliative care: how accurate are clinicians and who are the experts? PLoS One. 2016;11(8):e0161407. doi: 10.1371/journal.pone.0161407.
    1. Dalkey NC. The Delphi Method: an experimental study of group opinion. Santa Monica: RAND Corporation; 1969.
    1. Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2013;70(1):1–11. doi: 10.1007/s00228-013-1575-8.
    1. Marriott J, Stehlik P. A critical analysis of the methods used to develop explicit clinical criteria for use in older people. Age Ageing. 2012;41(4):441–450. doi: 10.1093/ageing/afs064.
    1. Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–875. doi: 10.1007/s00228-015-1860-9.
    1. Fried TR, Niehoff K, Tjia J, Redeker N, Goldstein MK. A Delphi process to address medication appropriateness for older persons with multiple chronic conditions. BMC Geriatr. 2016;16(1):67. doi: 10.1186/s12877-016-0240-3.
    1. Rodríguez-Pérez A, Alfaro-Lara ER, Albiñana-Perez S, Nieto-Martín MD, Díez-Manglano J, Pérez-Guerrero C, Santos-Ramos B. Novel tool for deprescribing in chronic patients with multimorbidity: list of evidence-based deprescribing for chronic patients criteria. Geriatr Gerontol Int. 2017;17(11):2200–2207. doi: 10.1111/ggi.13062.
    1. De Lima L, Radbruch L, Bruera E (2015) Essential medicines for palliative care. In: Cherny N, Fallon M, Kaasa S et al (eds) Oxford textbook of palliative medicine (5 ed.). Oxford University Press
    1. Levinson W, Kallewaard M, Bhatia RS, Wolfson D, Shortt S, Kerr EA, Choosing Wisely International Working Group ‘Choosing Wisely’: a growing international campaign. BMJ Qual Saf. 2015;24(2):167–174. doi: 10.1136/bmjqs-2014-003821.
    1. AGS Choosing Wisely Workgroup American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc. 2013;61(4):622–631. doi: 10.1111/jgs.12226.
    1. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195–198. doi: 10.1136/bmj.327.7408.195.
    1. Hui D. Prognostication of survival in patients with advanced cancer: predicting the unpredictable? Cancer Control. 2015;22(4):489–497. doi: 10.1177/107327481502200415.
    1. Parsons C. Withdrawal of antidementia drugs in older people: who, when and how? Drugs Aging. 2016;33(8):545–556. doi: 10.1007/s40266-016-0384-z.
    1. van der Cammen TJM, Rajkumar C, Onder G, et al. Drug cessation in complex older adults: time for action. Age Ageing. 2014;43(1):20–25. doi: 10.1093/ageing/aft166.
    1. Reeve E, Denig P, Hilmer SN, ter Meulen R. The ethics of deprescribing in older adults. J Bioeth Inq. 2016;13(4):581–590. doi: 10.1007/s11673-016-9736-y.
    1. De Schreye R, Houttekier D, Deliens L et al (2017) Developing indicators of appropriate and inappropriate end-of-life care in people with Alzheimer’s disease, cancer or chronic obstructive pulmonary disease for population-level administrative databases: a RAND/UCLA appropriateness study. Palliat Med:269216317705099
    1. Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47(5):702–713. doi: 10.1016/j.ejca.2010.11.027.
    1. Rayner L, Price A, Hotopf M, Higginson IJ. Expert opinion on detecting and treating depression in palliative care: a Delphi study. BMC Palliat Care. 2011;10(1):10. doi: 10.1186/1472-684X-10-10.
    1. Bush SH, Kanji S, Pereira JL, Davis DHJ, Currow DC, Meagher DJ, Rabheru K, Wright DK, Bruera E, Agar M, Hartwick M, Gagnon PR, Gagnon B, Breitbart W, Regnier L, Lawlor PG. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manag. 2014;48(2):231–248. doi: 10.1016/j.jpainsymman.2013.07.018.
    1. Lindqvist O, Lundquist G, Dickman A, Bükki J, Lunder U, Hagelin CL, Rasmussen BH, Sauter S, Tishelman C, Fürst CJ, OPCARE9 Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. J Palliat Med. 2013;16(1):38–43. doi: 10.1089/jpm.2012.0205.
    1. Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral Risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med. 2016;27(6):486–498.
    1. Schrijver EJM, de Vries OJ, van de Ven PM et al (2017) Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial. Age Ageing:1–8
    1. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684–706. doi: 10.1177/0269216317690685.
    1. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, Lewis IK, Landsman PB, Cohen HJ. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891–896. doi: 10.1016/0895-4356(94)90192-9.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する